Abstracts tagged "paraoxonase and rheumatoid arthritis (RA)"

Abstract Number: 66 • 2018 ACR/ARHP Annual Meeting
Suppression of Inflammatory Arthritis, in Human Paraoxonase 1 Transgenic Mice, Correlates with Upregulation of the Hepatic Glutathione Pathway and Reduction of Bioactive Lipid Mediators
Christina Charles-Schoeman¹, Ani Shahbazian², Jennifer Wang³, Xiaoyan Wang², Ernest Brahn², Jeremy Papesh², Victor Grijalva⁴ and Srinivasa T. Reddy², ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²University of California, Los Angeles, Los Angeles, CA, ³University of California Los Angeles, Los Angeles, CA, ⁴Medicine-Cardiology, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Paraoxonase 1 (PON1) is an HDL-associated protein, which hydrolyzes biologically active oxidized phospholipids and prevents oxidation of lipids in LDL and HDL. Increased lipid…
Abstract Number: 1562 • 2016 ACR/ARHP Annual Meeting
Interaction Between Antibodies to Paraoxonase 1 and PON1 rs662 Polymorphism: New Clues to Understand HDL Dysfunction and Oxidative Stress in Rheumatoid Arthritis
Javier Rodríguez-Carrio¹, Mercedes Alperi-López², Raquel López-Mejías³, Patricia López¹, Francisco Javier Ballina-García², Francisco Abal⁴, Miguel Angel Gonzalez-Gay^3,5 and Ana Suárez¹, ¹Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ²Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ⁴Centro de Salud Sariego, Siero, Servicio de Salud del Principado de Asturias (SESPA), Siero, Spain, ⁵School of Medicine, University of Cantabria, Santander, Spain
Background/Purpose: Traditional and non-traditional cardiovascular (CV) risk factors underlie CV disease occurrence in rheumatoid arthritis (RA). Recently, a functional impairment of HDL antioxidant capacity has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].